Tag Archives: DPP-4

April, 2015

  • 10 April

    FDA Says AstraZeneca’s Onglyza May Increase Death Risk

    The US Food and Drug Administration (FDA) staff reviewers have raised serious concerns of safety issues associated with AstraZeneca’s diabetes drug Onglyza. The agency’s concerns come a few days ahead of a committee meeting to discuss the safety of DPP-4 inhibitors. The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee is …